Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant Dose Escalation in Refractory Chronic Cough
NCT02349425Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gefapixant in refractory chronic cough (RCC), sponsored by Merck & Co.. Started Mar 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT02349425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349425.